Last reviewed · How we verify

Experimental dosing of labetalol

Albany Medical College · FDA-approved active Small molecule

Experimental dosing of labetalol is a Alpha-beta adrenergic antagonist Small molecule drug developed by Albany Medical College. It is currently FDA-approved for Hypertension, Hypertensive emergency.

Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking both alpha-1 and beta-adrenergic signaling.

Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking both alpha-1 and beta-adrenergic signaling. Used for Hypertension, Hypertensive emergency.

At a glance

Generic nameExperimental dosing of labetalol
SponsorAlbany Medical College
Drug classAlpha-beta adrenergic antagonist
TargetAlpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Labetalol's dual mechanism involves non-selective beta-blockade and selective alpha-1 blockade, resulting in reduced peripheral vascular resistance and decreased cardiac output. This combination produces antihypertensive effects with less reflex tachycardia than pure beta-blockers. The experimental dosing referenced likely involves investigation of novel dosing regimens or formulations of this established agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Experimental dosing of labetalol

What is Experimental dosing of labetalol?

Experimental dosing of labetalol is a Alpha-beta adrenergic antagonist drug developed by Albany Medical College, indicated for Hypertension, Hypertensive emergency.

How does Experimental dosing of labetalol work?

Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking both alpha-1 and beta-adrenergic signaling.

What is Experimental dosing of labetalol used for?

Experimental dosing of labetalol is indicated for Hypertension, Hypertensive emergency.

Who makes Experimental dosing of labetalol?

Experimental dosing of labetalol is developed and marketed by Albany Medical College (see full Albany Medical College pipeline at /company/albany-medical-college).

What drug class is Experimental dosing of labetalol in?

Experimental dosing of labetalol belongs to the Alpha-beta adrenergic antagonist class. See all Alpha-beta adrenergic antagonist drugs at /class/alpha-beta-adrenergic-antagonist.

What development phase is Experimental dosing of labetalol in?

Experimental dosing of labetalol is FDA-approved (marketed).

What are the side effects of Experimental dosing of labetalol?

Common side effects of Experimental dosing of labetalol include Fatigue, Dizziness, Headache, Nausea, Tremor, Bronchospasm.

What does Experimental dosing of labetalol target?

Experimental dosing of labetalol targets Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor and is a Alpha-beta adrenergic antagonist.

Related